Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ABBV34.SA
Strong BuyAbbVie Inc. · Healthcare · United States · $450.6B · Avg Vol: $13K/d
98
StockRankGet insider-trade alerts
Q
75
V
49
M
88
P/E (TTM)
72.8x
ROE
—
D/E
—
Dividend %
1.9%
COMPANY DESCRIPTION
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
FINANCIAL SUMMARY (BRL)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 302.2B | 282.7B | 293.2B | 318.4B | 1.8% | 335.2B | 351.8B | 382.7B | 9.6% |
| EPS (BRL) | 0.14 | 0.06 | 0.05 | 0.05 | -29.3% | — | — | — | — |
| Shares | 28.3B | 28.3B | 28.3B | 28.3B | 0.0% | 28.3B | — | — | — |
| Debt | 329.4B | 309.1B | 349.5B | 351.3B | 2.2% | 369.0B | — | — | — |
| Equity | 89.8B | 53.9B | 17.3B | -17.0B | -56.1% | — | — | — | — |
| Op CF | 129.8B | 118.9B | 97.9B | 99.1B | -8.6% | 101.5B | — | — | — |
| Inv CF | -3.2B | -10.5B | -108.4B | -34.6B | — | — | — | — | — |
| Fin CF | -129.1B | -89.6B | -27.1B | -66.2B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+2.4%
SMA 50SMA 200
Close
$16.01
RSI (14)
69.4
52W High
$16.70
From 52W High
1.0%
SCORE BREAKDOWN
Quality
75
ROIC
12.8%80.3
ROE
neg eq95.0
GP/Assets
35.0%72.4
Op. Margin
40.0%96.0
FCF/Assets
13.6%91.2
Piotroski
894.4
Int. Cover
4.0x50.0
D/E Ratio
neg eq50.0
Current Ratio
0.81x6.0
Value
49
P/E (TTM)
72.8x12.6
EV/EBITDA
1.3x98.8
P/FCF
24.7x52.5
P/B
-0.9x25.0
P/S
7.0x34.0
Div Yield
1.9%45.2
Momentum
88
52W High %
96%93.3
RS 6M
26%82.9
SMA 50/200
1.10x78.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
285%94.3
FUNDAMENTALS
Market Cap
$450.6B
P/E (Forward)
—
Gross Margin
72.8%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABBV34.SA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABBV34.SA | AbbVie Inc.(you) | $450.6B | 98 | Strong Buy |
| MRK.MX | Merck & Co., Inc. | $365.0B | 91 | Strong Buy |
| ROP.SW | Roche Holding AG | $353.1B | 88 | Strong Buy |
| JNJB34.SA | Johnson & Johnson | $641.4B | 89 | Strong Buy |
| N1VO34.SA | Novo Nordisk A/S | $201.0B | 98 | Strong Buy |
| AMG.DE | Amgen Inc. | $234.0B | 93 | Strong Buy |
| NOVN.SW | Novartis AG | $290.6B | 86 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $136.0B | 99 | Strong Buy |
| PFIZ34.SA | Pfizer Inc. | $158.4B | 93 | Strong Buy |
| LLY.MX | Eli Lilly and Company | $1.0T | 89 | Strong Buy |
Peer medians: ROE 2.1% · P/E 24.1x · Gross margin 52.5%